Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Paul A Vanderlaan, M.D., Ph.D.

Title
Institution
Department
Address
Phone
Profile Picture

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. VanderLaan PA. Non-small cell lung cancer predictive biomarker testing via immunocytochemistry: Ways of future past? Cancer Cytopathol. 2019 May; 127(5):278-280. PMID: 31050221.
    Citations:    
  2. Alagappan M, Darras N, Yang L, Vanderlaan P, Mizrahi M, Sawhney M, Pleskow DK, Berzin TM. Yield of biliary stent cytology: Is it time to think lean? Endosc Int Open. 2019 Apr; 7(4):E545-E550. PMID: 31041372.
    Citations:    
  3. de Margerie-Mellon C, VanderLaan PA, Bankier AA. CT Manifestations of Tumor Spread through Air Spaces in Lung Adenocarcinoma: Different Pathways toward Common Perspectives. Radiology. 2019 Jan; 290(1):271-272. PMID: 30511911.
    Citations:    Fields:    
  4. Chen Y, VanderLaan PA, Heher YK. False positive diagnosis of lymph node metastases in a 34-year-old woman with a history of extraskeletal myxoid chondroscarcoma: A root cause analysis. Cancer Cytopathol. 2019 Feb; 127(2):69-71. PMID: 30394675.
    Citations:    Fields:    
  5. de Margerie-Mellon C, Onken A, Heidinger BH, VanderLaan PA, Bankier AA. CT Manifestations of Tumor Spread Through Airspaces in Pulmonary Adenocarcinomas Presenting as Subsolid Nodules. J Thorac Imaging. 2018 Nov; 33(6):402-408. PMID: 30067571.
    Citations:    Fields:    
  6. Anderson KR, Onken A, Heidinger BH, Chen Y, Bankier AA, VanderLaan PA. Pathologic T Descriptor of Nonmucinous Lung Adenocarcinomas Now Based on Invasive Tumor Size: How Should Pathologists Measure Invasion? Am J Clin Pathol. 2018 Oct 24; 150(6):499-506. PMID: 30084917.
    Citations:    Fields:    
  7. Rivera E, Gesthalter Y, VanderLaan P, Parikh MS. Pulmonary Sclerosing Pneumocytoma. J Bronchology Interv Pulmonol. 2018 10; 25(4):e54-e56. PMID: 30247298.
    Citations:    Fields:    Translation:Humans
  8. VanderLaan PA, Rangachari D, Costa DB. Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018 09 13; 379(11):1093. PMID: 30211492.
    Citations:    Fields:    Translation:Humans
  9. VanderLaan PA. Updates in Lung Cancer Cytopathology. Surg Pathol Clin. 2018 Sep; 11(3):515-522. PMID: 30190138.
    Citations:    Fields:    Translation:Humans
  10. Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova EV, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Jänne PA. Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2018 Dec 01; 24(23):5963-5976. PMID: 30072474.
    Citations:    Fields:    
  11. Heher YK, Chen Y, VanderLaan PA. Pre-analytic error: A significant patient safety risk. Cancer Cytopathol. 2018 Aug; 126 Suppl 8:738-744. PMID: 30156766.
    Citations:    Fields:    
  12. Ravindran K, DiStasio M, Laham R, Ogilvy CS, Thomas AJ, VanderLaan PA, Alturki AY. Histopathological Demonstration of Subacute Endothelialization Following Aneurysm Retreatment with the Pipeline Embolization Device. World Neurosurg. 2018 Oct; 118:156-160. PMID: 30031197.
    Citations:    Fields:    Translation:Humans
  13. Sehgal K, Peters MLB, VanderLaan PA, Rangachari D, Kobayashi SS, Costa DB. Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer. J Thorac Oncol. 2019 Jan; 14(1):e1-e3. PMID: 29981924.
    Citations:    Fields:    
  14. Sclafani A, VanderLaan P. Lymphangioleiomyomatosis. N Engl J Med. 2018 Jun 07; 378(23):2224. PMID: 29874537.
    Citations:    Fields:    Translation:Humans
  15. VanderLaan PA, Chen Y, DiStasio M, Rangachari D, Costa DB, Heher YK. Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target. Clin Lung Cancer. 2018 09; 19(5):e589-e590. PMID: 29798809.
    Citations:    Fields:    
  16. Rangachari D, VanderLaan PA, Costa DB. Updated Correlation of 22C3-PD-L1 =50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting. J Thorac Oncol. 2018 05; 13(5):e81-e83. PMID: 29703544.
    Citations:    Fields:    
  17. Ostios-Garcia L, Faig J, Leonardi GC, Adeni AE, Subegdjo SJ, Lydon CA, Rangachari D, Huberman MS, Sehgal K, Shea M, VanderLaan PA, Cheng MP, Marty FM, Hammond SP, Costa DB, Awad MM. Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 07; 13(7):1037-1042. PMID: 29631035.
    Citations: 2     Fields:    
  18. Shea M, Rangachari D, Hallowell RW, Hollie NI, Costa DB, VanderLaan PA. Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis. Cancer Treat Res Commun. 2018; 15:17-20. PMID: 30207283.
    Citations:    
  19. Torous VF, Rangachari D, Gallant BP, Shea M, Costa DB, VanderLaan PA. PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option? J Am Soc Cytopathol. 2018 May-Jun; 7(3):133-141. PMID: 29713584.
    Citations: 3     
  20. VanderLaan PA, Rangachari D, Majid A, Parikh MS, Gangadharan SP, Kent MS, McDonald DC, Huberman MS, Kobayashi SS, Costa DB. Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer. 2018 02; 116:90-95. PMID: 29413057.
    Citations: 1     Fields:    
  21. Lastra RR, Birdsong G, Hwang DH, Jorda M, Kerr DA, McGrath C, Odronic S, Rao R, VanderLaan PA, Walker JW, Antic T. Preoperative cytologic interpretation of noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a 1-year multi-institutional experience. J Am Soc Cytopathol. 2018 Mar - Apr; 7(2):79-85. PMID: 31043256.
    Citations:    
  22. Heidinger BH, Anderson KR, Nemec U, Costa DB, Gangadharan SP, VanderLaan PA, Bankier AA. Morphologic characteristics of pulmonary adenocarcinomas manifesting as pure ground-glass nodules on CT. J Thorac Dis. 2017 Dec; 9(12):E1148-E1150. PMID: 29313855.
    Citations:    
  23. Carney BJ, Rangachari D, VanderLaan PA, Gowen K, Schrock AB, Ali SM, Costa DB. De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma. Lung Cancer. 2017 12; 114:108-110. PMID: 28870636.
    Citations: 2     Fields:    Translation:Humans
  24. Nemec U, Heidinger BH, Anderson KR, Westmore MS, VanderLaan PA, Bankier AA. Software-based risk stratification of pulmonary adenocarcinomas manifesting as pure ground glass nodules on computed tomography. Eur Radiol. 2018 Jan; 28(1):235-242. PMID: 28710575.
    Citations: 6     Fields:    Translation:Humans
  25. Heidinger BH, Nemec U, Anderson KR, Costa DB, Gangadharan SP, VanderLaan PA, Bankier AA. "Rounding" the Size of Pulmonary Nodules: Impact of Rounding Methods on Nodule Management, as Defined by the 2017 Fleischner Society Guidelines. Acad Radiol. 2017 11; 24(11):1422-1427. PMID: 28666724.
    Citations:    Fields:    Translation:Humans
  26. Rangachari D, Le X, Shea M, Huberman MS, VanderLaan PA, Kobayashi SS, Costa DB. Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. J Thorac Oncol. 2017 11; 12(11):e175-e177. PMID: 28611010.
    Citations: 2     Fields:    Translation:Humans
  27. Torous VF, Brancely D, VanderLaan PA. Implementation of the Paris System for Reporting Urinary Cytology results in lower atypical diagnostic rates. J Am Soc Cytopathol. 2017 Sep - Oct; 6(5):205-210. PMID: 31043244.
    Citations:    
  28. Heher YK, Chen Y, VanderLaan PA. Measuring and assuring quality performance in cytology: A toolkit. Cancer Cytopathol. 2017 06; 125(S6):502-507. PMID: 28609007.
    Citations:    Fields:    Translation:Humans
  29. Anderson KR, Heidinger BH, Chen Y, Bankier AA, VanderLaan PA. Measurement Bias of Gross Pathologic Compared With Radiologic Tumor Size of Resected Lung Adenocarcinomas: Implications for the T-Stage Revisions in the Eighth Edition of the American Joint Committee on Cancer Staging Manual. Am J Clin Pathol. 2017 Jun 01; 147(6):641-648. PMID: 28575179.
    Citations: 1     Fields:    Translation:Humans
  30. Heidinger BH, Anderson KR, Nemec U, Costa DB, Gangadharan SP, VanderLaan PA, Bankier AA. Lung Adenocarcinoma Manifesting as Pure Ground-Glass Nodules: Correlating CT Size, Volume, Density, and Roundness with Histopathologic Invasion and Size. J Thorac Oncol. 2017 08; 12(8):1288-1298. PMID: 28576745.
    Citations: 7     Fields:    Translation:Humans
  31. DiStasio M, Chen Y, Rangachari D, Costa DB, Heher YK, VanderLaan PA. Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis. Clin Lung Cancer. 2017 09; 18(5):e349-e356. PMID: 28377205.
    Citations: 2     Fields:    Translation:Humans
  32. Heidinger BH, Anderson KR, Moriarty EM, Costa DB, Gangadharan SP, VanderLaan PA, Bankier AA. Size Measurement and T-staging of Lung Adenocarcinomas Manifesting as Solid Nodules =30?mm on CT: Radiology-Pathology Correlation. Acad Radiol. 2017 07; 24(7):851-859. PMID: 28256438.
    Citations: 3     Fields:    Translation:Humans
  33. VanderLaan PA, Rangachari D, Mockus SM, Spotlow V, Reddi HV, Malcolm J, Huberman MS, Joseph LJ, Kobayashi SS, Costa DB. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer. 2017 04; 106:17-21. PMID: 28285689.
    Citations: 11     Fields:    Translation:Humans
  34. Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, Costa DB. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 =50% Expression in Lung Adenocarcinoma. J Thorac Oncol. 2017 05; 12(5):878-883. PMID: 28104537.
    Citations: 12     Fields:    Translation:Humans
  35. DuBrock HM, Rodriguez-Lopez JM, LeVarge BL, Curry MP, VanderLaan PA, Zsengeller ZK, Pernicone E, Preston IR, Yu PB, Nikolic I, Xu D, Thadhani RI, Channick RN, Ananth Karumanchi S. Macrophage migration inhibitory factor as a novel biomarker of portopulmonary hypertension. Pulm Circ. 2016 Dec; 6(4):498-507. PMID: 28090291.
    Citations: 1     
  36. Layfield LJ, Roy-Chowdhuri S, Baloch Z, Ehya H, Geisinger K, Hsiao SJ, Lin O, Lindeman NI, Roh M, Schmitt F, Sidiropoulos N, VanderLaan PA. Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology. Diagn Cytopathol. 2016 Dec; 44(12):1000-1009. PMID: 27561242.
    Citations: 1     Fields:    Translation:Humans
  37. Rangachari D, Drake L, Huberman MS, McDonald DC, VanderLaan PA, Folch E, Costa DB. Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice. Cancer Treat Commun. 2016; 9:41-43. PMID: 28111612.
    Citations:    
  38. Lucena-Araujo AR, Moran JP, VanderLaan PA, Dias-Santagata D, Folch E, Majid A, Kent MS, Gangadharan SP, Rangachari D, Huberman MS, Kobayashi SS, Costa DB. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers. Lung Cancer. 2016 09; 99:17-22. PMID: 27565908.
    Citations: 3     Fields:    Translation:HumansCells
  39. Sheikine Y, Rangachari D, McDonald DC, Huberman MS, Folch ES, VanderLaan PA, Costa DB. EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review. Clin Lung Cancer. 2016 11; 17(6):483-492. PMID: 27381270.
    Citations: 6     Fields:    Translation:Humans
  40. VanderLaan PA. Fine-needle aspiration and core needle biopsy: An update on 2 common minimally invasive tissue sampling modalities. Cancer Cytopathol. 2016 Dec; 124(12):862-870. PMID: 27182895.
    Citations: 1     Fields:    Translation:Humans
  41. Gao X, VanderLaan PA, Bailey AS, Costa DB. Comprehensive Genomic Profiling Differentiates Metachronous Primary Small-Cell Lung Cancer From Late Recurrence. Clin Lung Cancer. 2016 09; 17(5):e169-e172. PMID: 27103378.
    Citations:    Fields:    Translation:Humans
  42. Jorge SE, Schulman S, Freed JA, VanderLaan PA, Rangachari D, Kobayashi SS, Huberman MS, Costa DB. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer. 2015 Dec; 90(3):369-74. PMID: 26791794.
    Citations: 16     Fields:    Translation:HumansCells
  43. Torre M, Hwang DH, Padera RF, Mitchell RN, VanderLaan PA. Osseous and chondromatous metaplasia in calcific aortic valve stenosis. Cardiovasc Pathol. 2016 Jan-Feb; 25(1):18-24. PMID: 26386747.
    Citations: 1     Fields:    Translation:Humans
  44. Folch E, Costa DB, Wright J, VanderLaan PA. Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis. Transl Lung Cancer Res. 2015 Aug; 4(4):392-403. PMID: 26380180.
    Citations: 2     
  45. VanderLaan PA. Molecular markers: Implications for cytopathology and specimen collection. Cancer Cytopathol. 2015 Aug; 123(8):454-60. PMID: 25964216.
    Citations: 2     Fields:    Translation:Humans
  46. Klempner SJ, Ou SH, Costa DB, VanderLaan PA, Sanford EM, Schrock A, Gay L, Ali SM, Miller VA. The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review. Clin Lung Cancer. 2015 Sep; 16(5):334-339.e1. PMID: 25911330.
    Citations: 4     Fields:    Translation:Humans
  47. Le X, Freed JA, VanderLaan PA, Huberman MS, Rangachari D, Jorge SE, Lucena-Araujo AR, Kobayashi SS, Balasubramanian S, He J, Chudnovsky Y, Miller VA, Ali SM, Costa DB. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. Clin Lung Cancer. 2015 Sep; 16(5):e105-9. PMID: 25922291.
    Citations: 3     Fields:    Translation:Humans
  48. Cai Y, Hirata A, Nakayama S, VanderLaan PA, Levantini E, Yamamoto M, Hirai H, Wong KK, Costa DB, Watanabe H, Kobayashi SS. CCAAT/enhancer binding protein ß is dispensable for development of lung adenocarcinoma. PLoS One. 2015; 10(3):e0120647. PMID: 25767874.
    Citations:    Fields:    Translation:HumansAnimalsCells
  49. Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, Katayama R, Costa C, Ross KN, Moran T, Howe E, Fulton LE, Mulvey HE, Bernardo LA, Mohamoud F, Miyoshi N, VanderLaan PA, Costa DB, Jänne PA, Borger DR, Ramaswamy S, Shioda T, Iafrate AJ, Getz G, Rudin CM, Mino-Kenudson M, Engelman JA. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015 Mar 11; 6:6377. PMID: 25758528.
    Citations: 85     Fields:    Translation:HumansCells
  50. Le X, Desai NV, Majid A, Karp RS, Huberman MS, Rangachari D, Kent MS, Gangadharan SP, Folch E, VanderLaan PA, Costa DB. De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors. Lung Cancer. 2015 Apr; 88(1):70-3. PMID: 25700797.
    Citations: 5     Fields:    Translation:Humans
  51. Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, Dahlberg SE, Huberman MS, Costa DB. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 2015 Apr; 88(1):108-11. PMID: 25682925.
    Citations: 50     Fields:    Translation:Humans
  52. Marotti JD, Rao KP, Brister KJ, Gutmann EJ, Tsapakos MJ, Sheiman R, Wang HH, VanderLaan PA. Cytologic rapid on-site evaluation of transthoracic computed tomography-guided lung needle biopsies: who should perform ROSE? A cross-institutional analysis of procedural and diagnostic outcomes. J Am Soc Cytopathol. 2015 May - Jun; 4(3):160-169. PMID: 31051697.
    Citations:    
  53. Rangachari D, VanderLaan PA, Le X, Folch E, Kent MS, Gangadharan SP, Majid A, Haspel RL, Joseph LJ, Huberman MS, Costa DB. Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice. Cancer Treat Commun. 2015; 4:174-181. PMID: 26601054.
    Citations: 11     
  54. Donato J, Phillips CT, Gaffney AW, VanderLaan PA, Mouded M. A case of hypercalcemia secondary to hot tub lung. Chest. 2014 Dec; 146(6):e186-e189. PMID: 25451359.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  55. Mahajan AK, Ibrahim O, Shostak E, VanderLaan PA, Majid A, Folch E. EBUS-TBNA of pulmonary artery clot. J Bronchology Interv Pulmonol. 2014 Oct; 21(4):371-3. PMID: 25321465.
    Citations:    Fields:    Translation:Humans
  56. Burke KE, VanderLaan PA, Folch E, Curry MP, McSparron JI. A 50-year-old man with cirrhosis and progressive hypoxemia. Ann Am Thorac Soc. 2014 Sep; 11(7):1149-51. PMID: 25237994.
    Citations:    Fields:    Translation:Humans
  57. VanderLaan PA, Wang HH, Majid A, Folch E. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA): an overview and update for the cytopathologist. Cancer Cytopathol. 2014 Aug; 122(8):561-76. PMID: 24760496.
    Citations: 13     Fields:    Translation:Humans
  58. Jawad A, Majid A, Maskey A, Vanderlaan P, Ibrahim OM, Folch E. Pill aspiration presenting as an endobronchial tumor. J Bronchology Interv Pulmonol. 2014 Apr; 21(2):162-5. PMID: 24739693.
    Citations:    Fields:    Translation:Humans
  59. Steinhaus D, Gelfand E, VanderLaan PA, Kociol RD. Recovery of giant-cell myocarditis using combined cytolytic immunosuppression and mechanical circulatory support. J Heart Lung Transplant. 2014 Jul; 33(7):769-71. PMID: 24656644.
    Citations: 2     Fields:    Translation:Humans
  60. Vanderlaan PA, Yamaguchi N, Folch E, Boucher DH, Kent MS, Gangadharan SP, Majid A, Goldstein MA, Huberman MS, Kocher ON, Costa DB. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. Lung Cancer. 2014 Apr; 84(1):39-44. PMID: 24513263.
    Citations: 30     Fields:    Translation:Humans
  61. Folch E, Yamaguchi N, VanderLaan PA, Kocher ON, Boucher DH, Goldstein MA, Huberman MS, Kent MS, Gangadharan SP, Costa DB, Majid A. Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer. J Thorac Oncol. 2013 Nov; 8(11):1438-1444. PMID: 24128714.
    Citations: 9     Fields:    Translation:Humans
  62. Chan B, VanderLaan PA, Sukhatme VP. 6-Phosphogluconate dehydrogenase regulates tumor cell migration in vitro by regulating receptor tyrosine kinase c-Met. Biochem Biophys Res Commun. 2013 Sep 20; 439(2):247-51. PMID: 23973484.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  63. Yamaguchi N, Vanderlaan PA, Folch E, Boucher DH, Canepa HM, Kent MS, Gangadharan SP, Majid A, Kocher ON, Goldstein MA, Huberman MS, Costa DB. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. Lung Cancer. 2013 Oct; 82(1):31-7. PMID: 23932486.
    Citations: 18     Fields:    Translation:Humans
  64. Sethi R, Kozin E, Remenschneider A, Meier J, VanderLaan P, Faquin W, Deschler D, Frankenthaler R. Mammary analogue secretory carcinoma: update on a new diagnosis of salivary gland malignancy. Laryngoscope. 2014 Jan; 124(1):188-195. PMID: 23775296.
    Citations: 8     Fields:    Translation:Humans
  65. Hamaji M, Vanderlaan PA, Sugarbaker DJ, McNamee CJ. A microthymoma and no germinal centre in myasthenia gravis. Eur J Cardiothorac Surg. 2013 Dec; 44(6):1146-7. PMID: 23588037.
    Citations: 1     Fields:    Translation:Humans
  66. Srivastava N, VanderLaan PA, Kelly CP, Costa DB. Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer. J Thorac Oncol. 2013 Mar; 8(3):e23-4. PMID: 23407563.
    Citations: 3     Fields:    Translation:Humans
  67. VanderLaan PA, Padera RF, Schoen FJ. Practical Approach to the Evaluation of Prosthetic Mechanical and Tissue Replacement Heart Valves. Surg Pathol Clin. 2012 Jun; 5(2):353-69. PMID: 26838108.
    Citations:    Fields:    
  68. VanderLaan PA, Marqusee E, Krane JF. Features associated with locoregional spread of papillary carcinoma correlate with diagnostic category in the Bethesda System for reporting thyroid cytopathology. Cancer Cytopathol. 2012 Aug 25; 120(4):245-53. PMID: 22434789.
    Citations: 7     Fields:    Translation:Humans
  69. VanderLaan PA, Renshaw AA, Krane JF. Atypia of undetermined significance and nondiagnostic rates in The Bethesda System for Reporting Thyroid Cytopathology are inversely related. Am J Clin Pathol. 2012 Mar; 137(3):462-5. PMID: 22338059.
    Citations: 3     Fields:    Translation:Humans
  70. Vanderlaan PA, Krane JF, Cibas ES. The frequency of 'atypia of undetermined significance' interpretations for thyroid fine-needle aspirations is negatively correlated with histologically proven malignant outcomes. Acta Cytol. 2011; 55(6):512-7. PMID: 22156459.
    Citations: 6     Fields:    Translation:Humans
  71. Jo VY, Vanderlaan PA, Marqusee E, Krane JF. Repeatedly nondiagnostic thyroid fine-needle aspirations do not modify malignancy risk. Acta Cytol. 2011; 55(6):539-43. PMID: 22156463.
    Citations: 6     Fields:    Translation:Humans
  72. VanderLaan PA, Marqusee E, Krane JF. Usefulness of diagnostic qualifiers for thyroid fine-needle aspirations with atypia of undetermined significance. Am J Clin Pathol. 2011 Oct; 136(4):572-7. PMID: 21917679.
    Citations: 11     Fields:    Translation:Humans
  73. Getz GS, Vanderlaan PA, Reardon CA. Natural killer T cells in lipoprotein metabolism and atherosclerosis. Thromb Haemost. 2011 Nov; 106(5):814-9. PMID: 21946866.
    Citations: 15     Fields:    Translation:HumansAnimalsCells
  74. Krane JF, Vanderlaan PA, Faquin WC, Renshaw AA. The atypia of undetermined significance/follicular lesion of undetermined significance:malignant ratio: a proposed performance measure for reporting in The Bethesda System for thyroid cytopathology. Cancer Cytopathol. 2012 Apr 25; 120(2):111-6. PMID: 21919213.
    Citations: 7     Fields:    Translation:Humans
  75. VanderLaan PA, Marqusee E, Krane JF. Clinical outcome for atypia of undetermined significance in thyroid fine-needle aspirations: should repeated fna be the preferred initial approach? Am J Clin Pathol. 2011 May; 135(5):770-5. PMID: 21502433.
    Citations: 31     Fields:    Translation:Humans
  76. Fairweather M, Burt BM, VanderLaan PA, Brunker PA, Bafford AC, Ashley SW. Acute hemorrhage from small bowel diverticula harboring strongyloidiasis and schistosomiasis. Am Surg. 2010 May; 76(5):539-41. PMID: 20506887.
    Citations:    Fields:    Translation:HumansAnimals
  77. VanderLaan PA, Reardon CA, Thisted RA, Getz GS. VLDL best predicts aortic root atherosclerosis in LDL receptor deficient mice. J Lipid Res. 2009 Mar; 50(3):376-85. PMID: 18957695.
    Citations: 17     Fields:    Translation:HumansAnimals
  78. Getz GS, Vanderlaan PA, Reardon CA. The immune system and murine atherosclerosis. Curr Drug Targets. 2007 Dec; 8(12):1297-306. PMID: 18220706.
    Citations: 5     Fields:    Translation:AnimalsCellsPHPublic Health
  79. VanderLaan PA, Reardon CA, Sagiv Y, Blachowicz L, Lukens J, Nissenbaum M, Wang CR, Getz GS. Characterization of the natural killer T-cell response in an adoptive transfer model of atherosclerosis. Am J Pathol. 2007 Mar; 170(3):1100-7. PMID: 17322392.
    Citations: 26     Fields:    Translation:AnimalsCells
  80. Vanderlaan PA, Reardon CA. Thematic review series: the immune system and atherogenesis. The unusual suspects:an overview of the minor leukocyte populations in atherosclerosis. J Lipid Res. 2005 May; 46(5):829-38. PMID: 15772419.
    Citations: 22     Fields:    Translation:HumansCells
  81. VanderLaan PA, Reardon CA, Getz GS. Site specificity of atherosclerosis: site-selective responses to atherosclerotic modulators. Arterioscler Thromb Vasc Biol. 2004 Jan; 24(1):12-22. PMID: 14604830.
    Citations: 140     Fields:    Translation:HumansAnimals
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Vanderlaan's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (284)
Explore
_
Co-Authors (87)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.